F-18 FDG PET for assessing tyrosine kinase-related signal transduction inhibition in a GIST c-Kit-positive tumor patient by imatinib

Clinical Nuclear Medicine

Volumn 30, Issue 11, 2005, Pages 749-751

  Zaknun, John J ^a,b   Kendler, Doris ^a   Moncayo, Roy ^a   Zur Nedden, Dieter ^a   Virgolini, Irene ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b PET Zentrum   (Austria)

Author keywords

18FDG PET; GIST; Imatinib; Peritoneal involvement

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IMATINIB; PROTEIN TYROSINE KINASE; STEM CELL FACTOR;

ADULT; APPARATUS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC IMAGING; DRUG RESPONSE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IMAGE ANALYSIS; MALE; POSITRON EMISSION TOMOGRAPHY; SIGNAL TRANSDUCTION; SYMPTOM;

ANTINEOPLASTIC AGENTS; FLUORODEOXYGLUCOSE F18; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RADIOPHARMACEUTICALS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 27644502388     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rlu.0000182274.86579.65     Document Type: Article

References (8)

1. Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 2001;61:8118-8121.
2. Singer S, Rubin BP, Lux ML, et al. Prognostic value of KIT mutation type, mitotic activity and histological subtype in gastrointestinal stromal tumors. J Clin Oncol. 2002;20:3898-3905.
3. Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with flow cytometry and tritiated thymidine uptake. J Nucl Med. 1993;34:414-419.
4. Minn H, Joensuu H, Ahonen A, et al. Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with flow cytometry in head and neck tumors. Cancer. 1988;61:1776-1781.
5. Folpe AL, Lyles RH, Sprouse JT, et al. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res. 2000;6:1279-1287.
6. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344:1052-1056.
7. Demetri OD, von Mehren M, Blanke CD, et al. Efficacy and safety of Imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-480.
8. Stroobants S, Goeminne J, Seegers M, et al. FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer. 2003;39:2012-2020.